NASDAQ$ATAI
AtaiBeckley Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Atai Life Sciences reported a narrower net loss in Q2 2025 compared to the prior year, with slight revenue growth and steady R&D investment amid progress in its psychedelic treatment pipeline.
Atai Life Sciences reduced its net loss to $27.7 million in Q2 2025 and posted $719,000 in revenue, while advancing key clinical programs including BPL-003 and VLS-01. The company strengthened its financial position and continued progressing strategic milestones.
- Net loss attributable to shareholders narrowed to $27.7 million in Q2 2025 from $57.3 million in Q2 2024.
- Q2 2025 revenue was $719,000, up from $273,000 in Q2 2024.
- Cash and cash equivalents totaled $61.9 million, with total assets of $189.2 million.
- Company expects to fund operations into the second half of 2027 following additional July funding.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$719K
Forward guidance
Atai anticipates topline Phase 2b and 2a data for BPL-003 in Q3 2025 and is planning for a regulatory meeting with the FDA, while its VLS-01 and EMP-01 trials continue enrolling.
Tailwinds
- BPL-003 met all endpoints in Phase 2b and showed rapid, durable antidepressant effects.
- End-of-Phase 2 FDA meeting for BPL-003 planned for Q3 2025.
- Company expects funding runway into the second half of 2027.
- EMP-01 and VLS-01 clinical trials remain active and progressing.
- Atai plans strategic combination with Beckley Psytech to consolidate leadership in psychedelics.
Headwinds
- Primary endpoint not met in inidascamine Phase 2b trial.
- Delays in site activation and recruitment for VLS-01 Phase 2 trial.
- Higher G&A expenses due to strategic restructuring and redomiciliation efforts.
- Potential risks around pending shareholder approvals for Beckley combination.
- Operating cash use in Q2 totaled $31.9 million, pressuring near-term liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+1.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | -6.0% | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro